More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$103005120
EPS
0.19
P/E ratio
122.5
Price to sales
2.9
Dividend yield
--
Beta
0.616404
Previous close
$11.42
Today's open
$11.46
Day's range
$10.79 - $11.73
52 week range
$4.52 - $12.10
show more
CEO
Olivier te Boekhorst
Employees
73
Headquarters
Portland, ME
Exchange
NASDAQ Capital Market
Shares outstanding
9091361
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
ImmuCell Q3 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported a 46% increase in third-quarter product sales and returned to profitability as improved manufacturing output and stronger demand supported its First Defense calf-health products.
MarketBeat • Nov 13, 2026

ImmuCell Corporation (ICCC) Q3 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 13, 2026

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026
PORTLAND, Maine, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended September 30, 2026.
GlobeNewsWire • Nov 12, 2026

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026
Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET
GlobeNewsWire • Nov 6, 2026

ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
Zacks Investment Research • Oct 21, 2026

ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the third quarter of 2026.
GlobeNewsWire • Oct 12, 2026

SRK Capital 2026 Semi-Annual Portfolio Update
SRK Fund I, LP increased 26.80% during the first half of the year. In contrast, the S&P 500 and the Russell 2000 returned 10.18% and 22.57%, respectively. ImmuCell delivered a strong first quarter in 2026, underscoring the earnings power and cash-flow potential of its core First Defense franchise after the company's strategic exit from Re-Tain. Since divesting its capital-intensive ammunition manufacturing business in April 2025, Outdoor Holding Company has operated as a pure-play, asset-light marketplace through GunBroker.com.
Seeking Alpha • Sep 21, 2026

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
Zacks Investment Research • Aug 27, 2026

ImmuCell Q2 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
MarketBeat • Aug 14, 2026

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ImmuCell Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.